Research programme: small molecules - IM Therapeutics

Drug Profile

Research programme: small molecules - IM Therapeutics

Alternative Names: IMT 002; Methyldopa D-enantiomer

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Colorado at Denver
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type 1 diabetes mellitus
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Type 1 diabetes mellitus
  • Research Autoimmune disorders

Most Recent Events

  • 06 Dec 2017 IM Therapeutics licenses worldwide rights to methyldopa and D enantiomer of methyldopa from the University of Colorado
  • 06 Dec 2017 IM Therapeutics has patent protection for Methyldopa and D enantiomer of methyldopa (IMT 002) in USA
  • 10 Nov 2017 Preclinical trials in Type-1 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top